Join Boehringer Ingelheim and be part of a legacy where your growth is just as important as ours. A global, research-driven pharmaceutical company, we are one of the world’s top 20 leading pharmaceutical companies and have collaborated and innovated medicines in Human Pharma, Animal Health and Biopharmaceutical everywhere in the world for over 130 years. This is your chance to create ‘Value through Innovation’ with our internal and external partners to improve lives around the world, explore new scientific breakthroughs to stay at the forefront of our industry, and become a leader for future generations. We continue to grow fast and are one of the top growing companies in the industry in China. Join us and be part of our continued journey to grow and achieve BI global Ambition 2025.

As a leading company, Boehringer Ingelheim thrives on passion, innovation and independence, and offers fulfilling work and growing opportunities to highly dedicated people. Certified as Top Employer in China in the past 6 continuous years, we help our people grow towards their success through high quality career development programmes and opportunities to lead international projects to develop into a leader of tomorrow. At the end of the day, your growth is our growth and vice versa.

For more information, please

1. visit https://www.boehringer-ingelheim.com/ or

2. follow us on LinkedIn, or

3. follow us on WeChat – JoinBI

About Animal Health Business

At Boehringer Ingelheim, we are passionate about and committed to providing customers with better and innovative solutions as well as high-quality services in a bid to help improve food safety and animal welfare. We know that when animals are healthy, humans are healthier, too.

As the leading animal health company in China, we have extensive business coverage from the full value chain in R&D, production to sales; and a diversified product portfolio covering swine, poultry, pets, cattle vaccines and medicines. We set up the first, world-class AH R&D centre specialising in animal health products among MNCs in China with around EUR 12 million investments, and launched Asia’s leading animal vaccine production base in Taizhou, which will develop and manufacture high-quality swine vaccine products for China market. We are always “in China and for China”. We’ve pioneered many game-changers in the veterinary medicine, and we’re looking to our customers’ needs to guide us into the future.

Job Responsibilities

• Prepare monthly closing reporting and make analysis on site performance accurately within the given deadlines.
• Assist in budget preparation.
• Monitor & maintain SAP data and support the trouble shooting if necessary.
• Provide financial analytical and supports on site & specific projects.
• Assist in internal control management and ensure related policies are followed.

Qualifications

• Education/Degree Requirements:College degree in finance or related field with a minimum of 5 years working experience
• Language skills & proficiency
• Required capabilities (skills, experience, competencies
• Intermediate English skills– oral and written.
• Good computer knowledge of Office software, knowledge of accounting software is a plus.
• Strong financial analytical abilities.
• Good interpersonal and communication skills.
• Responsible and conscientious. Able to work under stress.

Behaviours

• Accountabilities – Even in ambiguous circumstances, always demonstrate ownership for decisions and actions
• Agility – Quickly act with an open mind to face internal and external transformation
• Intrapreneurship – Together with customers, come up with innovativeideas to respond to changing markets
  

Contact Us

If you think you can convince us that you are the right candidate we are looking for, apply now!

上班地址：南昌市

所属部门：职能部门

勃林格殷格翰公司由阿尔伯特·勃林格先生于1885年在德国中部莱茵河畔的殷格翰市创建，至今仍是家族企业。一百多年来，秉承“创新展现价值，研发驱动成长”的传统，公司从德国莱茵河畔延伸向全球超过40个国家和地区。公司是全球前20大制药企业之一。在人用药品、动物保健和生物制药合同生产三个业务领域，全球约5万名员工每天都在努力通过创新展现价值。
勃林格殷格翰始终致力于改善患者的健康与生活质量，专注于探索尚未出现有效治疗方案的疾病领域。公司着力开发创新疗法，帮助患者延长生命。勃林格殷格翰的人用药产品覆盖心血管代谢疾病、中枢神经疾病、免疫及呼吸疾病和肿瘤研究与癌症免疫学等重要治疗领域。公司在全球局有四个人用药品研发中心，在小分子和生物制药方面均拥有全面的研发能力。公司战略支柱之一的“跨边界研究”(RBB)，通过探索研究新兴科学、新适应症和新技术，来补充公司核心治疗领域，从而扩大研发机会。
作为全球第二大动物保健企业，勃林格殷格翰是经济动物和宠物抗寄生虫药及疫苗的全球顶尖供应商。通过提供先进的、预防性的动物保健，保护动物免受病痛困扰。公司提供新型的治疗手段帮助动物照料者们更有效地管理慢性疾病、减少疼痛、延缓疾病进展。
作为生物医药领域的先行者，早在上世纪60年代，公司就开展了生物药物科研开发以及生产的相关工作。历经半个多世纪的辛勤耕耘，勃林格殷格翰通过合同生产，共将多达27个生物药物成功地推向全球市场，造福全世界的患者。
作为一家家族企业，勃林格殷格翰目光长远，专注于长期成功，而不是短期利润。公司致力于通过自身资源实现有机增长，同时积极寻求研发领域的合作伙伴与战略联盟。此外，公司的一切行为都为人类和环境负责。
勃林格殷格翰于1994年正式进入中国市场，目前在华投资总额超过3亿欧元。公司管理总部位于上海，业务遍布全国，拥有员工超4000名。勃林格殷格翰中国近年来发展迅速，包括人用药品、动物保健、生物制药三大核心业务板块并驾齐驱，协调发展，推动公司持续增长。
秉承公司在一个多世纪的发展历程中所积累的雄厚实力，在过去的20多年，勃林格殷格翰致力于为中国医疗健康事业做出杰出贡献。公司对于中国市场的长期承诺和持续投资，推动勃林格殷格翰中国进入了一条高速发展的“快车道”。
在勃林格殷格翰中国，企业对员工、患者、业务伙伴、所在社区的承诺和关怀体现在诸多方面，肩负社会责任是公司创立至今始终坚守的企业信条之一。2014-2019年，公司连续六年蝉联“中国杰出雇主”认证。